Risk stratification is essential for guiding individualized preventive treatment to reduce sudden cardiac death in patients with hypertrophic cardiomyopathy.
Answers are grounded in this paper and cite their sources.
Risk stratification enables targeted SCD prevention in HCM; confirms guideline-endorsed algorithms for individualized therapy.
One of the clinical scenarios of hypertrophic cardiomyopathy (HCMP) is sudden cardiac death (SCD). The stratification of SCD risk is the key component of defining the therapeutic strategy in HCMP patients. Timely preventive treatment is the only life-saving intervention in patients with high SCD risk. The available clinical evidence suggests that SCD risk stratification is an effective algorithm for determining the need for preventive treatment. The latter should be individualised, based on the risk levels in each patient.
No takes yet. Share an insight, caveat, or question.
Привалова et al. (2013) conducted a review in Hypertrophic cardiomyopathy (HCMP). Sudden cardiac death risk stratification was evaluated. Risk stratification for sudden cardiac death in patients with hypertrophic cardiomyopathy is an effective algorithm for determining the need for individualized preventive treatment.
Synapse has enriched 10 related papers. Consider them for comparative context: